High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing

Zaal Meher-Homji; Constantine S. Tam; Jim Siderov; John Francis Seymour; Natasha E. Holmes; Kyra Y.L. Chua; Elizabeth J. Phillips; Monica A. Slavin; Jason A. Trubiano

doi:10.1080/10428194.2019.1633640

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing

Zaal Meher-Homji
, Constantine S. Tam
, Jim Siderov
, John Francis Seymour
, Natasha E. Holmes
, Kyra Y.L. Chua
, Elizabeth J. Phillips
, Monica A. Slavin
, Jason A. Trubiano

Research output: Contribution to journal › Article › Research › peer-review

5 Citations (Scopus)

Abstract

The relationship between hematological malignancy and chemotherapy on the prevalence of antibiotic allergy label (AAL) is ill-defined. We performed a multicenter retrospective case-control study comparing AAL rates among cladribine-treated hairy cell leukemia (C-HCL) cases, non-HCL cladribine-treated controls (control-1), and fludarabine-treated controls (control-2). The prevalence of AALs in C-HCL patients was 60%, compared with control-1 (14%, p <.01) and control-2 patients (25%, p <.01). The predominant phenotype was maculopapular exanthem (92%). The drugs implicated in AAL causality in C-HCL patients included beta-lactams (81%), trimethoprim–sulfamethoxazole (58%), and allopurinol (69%). C-HCL patients demonstrate high rates of AAL, potentially due to immune dysregulation, impacting beta-lactam utilization.

Original language	English
Pages (from-to)	3455-3460
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	60
Issue number	14
DOIs	https://doi.org/10.1080/10428194.2019.1633640
Publication status	Published - 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

allergy
antibiotics
cladribine
Hairy cell leukemia
maculopapular exanthem

Access to Document

10.1080/10428194.2019.1633640

Cite this

Meher-Homji, Z., Tam, C. S., Siderov, J., Seymour, J. F., Holmes, N. E., Chua, K. Y. L., Phillips, E. J., Slavin, M. A., & Trubiano, J. A. (2019). High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma, 60(14), 3455-3460. https://doi.org/10.1080/10428194.2019.1633640

@article{7939e31183f045388dbca48dd920f1c4,

title = "High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing",

abstract = "The relationship between hematological malignancy and chemotherapy on the prevalence of antibiotic allergy label (AAL) is ill-defined. We performed a multicenter retrospective case-control study comparing AAL rates among cladribine-treated hairy cell leukemia (C-HCL) cases, non-HCL cladribine-treated controls (control-1), and fludarabine-treated controls (control-2). The prevalence of AALs in C-HCL patients was 60\%, compared with control-1 (14\%, p <.01) and control-2 patients (25\%, p <.01). The predominant phenotype was maculopapular exanthem (92\%). The drugs implicated in AAL causality in C-HCL patients included beta-lactams (81\%), trimethoprim–sulfamethoxazole (58\%), and allopurinol (69\%). C-HCL patients demonstrate high rates of AAL, potentially due to immune dysregulation, impacting beta-lactam utilization.",

keywords = "allergy, antibiotics, cladribine, Hairy cell leukemia, maculopapular exanthem",

author = "Zaal Meher-Homji and Tam, \{Constantine S.\} and Jim Siderov and Seymour, \{John Francis\} and Holmes, \{Natasha E.\} and Chua, \{Kyra Y.L.\} and Phillips, \{Elizabeth J.\} and Slavin, \{Monica A.\} and Trubiano, \{Jason A.\}",

note = "Funding Information: This work was supported by an early career fellowship from the Australian National Health and Medical Research Council (1139902 to JAT). Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2019",

doi = "10.1080/10428194.2019.1633640",

language = "English",

volume = "60",

pages = "3455--3460",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor \& Francis",

number = "14",

}

TY - JOUR

T1 - High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing

AU - Meher-Homji, Zaal

AU - Tam, Constantine S.

AU - Siderov, Jim

AU - Seymour, John Francis

AU - Holmes, Natasha E.

AU - Chua, Kyra Y.L.

AU - Phillips, Elizabeth J.

AU - Slavin, Monica A.

AU - Trubiano, Jason A.

N1 - Funding Information: This work was supported by an early career fellowship from the Australian National Health and Medical Research Council (1139902 to JAT). Publisher Copyright: © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019

Y1 - 2019

N2 - The relationship between hematological malignancy and chemotherapy on the prevalence of antibiotic allergy label (AAL) is ill-defined. We performed a multicenter retrospective case-control study comparing AAL rates among cladribine-treated hairy cell leukemia (C-HCL) cases, non-HCL cladribine-treated controls (control-1), and fludarabine-treated controls (control-2). The prevalence of AALs in C-HCL patients was 60%, compared with control-1 (14%, p <.01) and control-2 patients (25%, p <.01). The predominant phenotype was maculopapular exanthem (92%). The drugs implicated in AAL causality in C-HCL patients included beta-lactams (81%), trimethoprim–sulfamethoxazole (58%), and allopurinol (69%). C-HCL patients demonstrate high rates of AAL, potentially due to immune dysregulation, impacting beta-lactam utilization.

AB - The relationship between hematological malignancy and chemotherapy on the prevalence of antibiotic allergy label (AAL) is ill-defined. We performed a multicenter retrospective case-control study comparing AAL rates among cladribine-treated hairy cell leukemia (C-HCL) cases, non-HCL cladribine-treated controls (control-1), and fludarabine-treated controls (control-2). The prevalence of AALs in C-HCL patients was 60%, compared with control-1 (14%, p <.01) and control-2 patients (25%, p <.01). The predominant phenotype was maculopapular exanthem (92%). The drugs implicated in AAL causality in C-HCL patients included beta-lactams (81%), trimethoprim–sulfamethoxazole (58%), and allopurinol (69%). C-HCL patients demonstrate high rates of AAL, potentially due to immune dysregulation, impacting beta-lactam utilization.

KW - allergy

KW - antibiotics

KW - cladribine

KW - Hairy cell leukemia

KW - maculopapular exanthem

UR - https://www.scopus.com/pages/publications/85068503175

U2 - 10.1080/10428194.2019.1633640

DO - 10.1080/10428194.2019.1633640

M3 - Article

C2 - 31256738

AN - SCOPUS:85068503175

SN - 1042-8194

VL - 60

SP - 3455

EP - 3460

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 14

ER -

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

MMT: Manure technologies for enhanced resource use efficiency

Cite this

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia–lessons for immunopathogenesis and prescribing

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Projects

MMT: Manure technologies for enhanced resource use efficiency

Cite this